Image

Impact of an Information Sheet Given to Parents After an Initial Consultation for a Simple Febrile Seizure at Strasbourg University Hospital

Impact of an Information Sheet Given to Parents After an Initial Consultation for a Simple Febrile Seizure at Strasbourg University Hospital

Recruiting
9-5 years
All
Phase N/A

Powered by AI

Overview

Simple febrile seizures (SFS) are a very common phenomenon (2-5% of children), mostly without serious consequences for the child or their development, but extremely anxiety-provoking for parents, who develop a "fear of fever" for fear of a recurrence, and request numerous additional tests, not justified according to current guidelines, after a first episode of SFS.

Educating parents about these fever-related crises and fever management, and standardizing the information provided through an explanatory sheet implemented at the SAUP in July 2023, would help reduce consultations for recurrent simple febrile crises, as well as early consultations for isolated fever (reflecting parental anxiety caused by these crises).

Eligibility

Inclusion Criteria:

  • Child aged between 9 months and 5 years at the time of consultation at the SAUP (emergency pediatric unit)
  • First visit to the SAUP for a simple febrile seizure
  • Meeting the clinical criteria for FCS:
    • Generalized seizure lasting less than 15 minutes
    • No post-critical deficit
    • No recurrence of seizures within 24 hours
    • No personal history of neurological disorders
  • Occurrence between January 1, 2022, and May 1, 2025
  • First or second episode of FSFS at the time of consultation
  • Presence of one of the two parents during the consultation at the SAUP

Exclusion Criteria:

  • Patient already seen at the SAUP for FCS
  • Child who has already had more than two simple febrile seizures at the time of their visit to the emergency department.
  • Child who does not meet the criteria for simple febrile seizures:
  • aged less than 9 months or more than 5 years at the time of diagnosis.
  • Non-febrile seizure
  • Focal seizure
  • Seizure duration \>15 min
  • Presence of post-critical deficit
  • Multiple seizures within 24 hours
  • Personal neurological history.
  • Seizure occurring outside the period of interest (January 1, 2022 to May 1, 2025)
  • Absence of parents during the SAUP consultation

Study details
    Febrile Crisis

NCT07335640

University Hospital, Strasbourg, France

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.